[{"address1": "4546 El Camino Real", "address2": "Suite B1", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 284 4433", "fax": "650 397 4433", "website": "https://renovorx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.", "fullTimeEmployees": 8, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ramtin  Agah M.D.", "age": 56, "title": "Founder, Chairman of Board & Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 332894, "exercisedValue": 0, "unexercisedValue": 173000}, {"maxAge": 1, "name": "Mr. Shaun R. Bagai", "age": 46, "title": "CEO & Director", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 589376, "exercisedValue": 0, "unexercisedValue": 304200}, {"maxAge": 1, "name": "Mr. Ronald B. Kocak CPA, CGMA", "age": 66, "title": "VP, Controller & Principal Accounting Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leesa  Gentry", "age": 53, "title": "Chief Clinical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.23, "open": 1.235, "dayLow": 1.21, "dayHigh": 1.2499, "regularMarketPreviousClose": 1.23, "regularMarketOpen": 1.235, "regularMarketDayLow": 1.21, "regularMarketDayHigh": 1.2499, "beta": 1.041, "forwardPE": -2.9512196, "volume": 3406, "regularMarketVolume": 3406, "averageVolume": 48729, "averageVolume10days": 10930, "averageDailyVolume10Day": 10930, "bid": 0.8856, "ask": 1.58, "bidSize": 200, "askSize": 200, "marketCap": 28979258, "fiftyTwoWeekLow": 0.531, "fiftyTwoWeekHigh": 3.29, "fiftyDayAverage": 1.38422, "twoHundredDayAverage": 1.35874, "currency": "USD", "enterpriseValue": 19234830, "floatShares": 15821802, "sharesOutstanding": 23949800, "sharesShort": 65482, "sharesShortPriorMonth": 15634, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.097849995, "heldPercentInstitutions": 0.01964, "shortRatio": 1.04, "shortPercentOfFloat": 0.0028, "impliedSharesOutstanding": 23949800, "bookValue": -0.281, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -10232000, "trailingEps": -0.99, "forwardEps": -0.41, "enterpriseToEbitda": -1.689, "52WeekChange": -0.6134185, "SandP52WeekChange": 0.21080327, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNXT", "underlyingSymbol": "RNXT", "shortName": "RenovoRx, Inc.", "longName": "RenovoRx, Inc.", "firstTradeDateEpochUtc": 1629984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6babfc24-dc5c-3de1-bf9d-2ec73346783e", "messageBoardId": "finmb_236111504", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.21, "targetHighPrice": 7.0, "targetLowPrice": 3.5, "targetMeanPrice": 4.83, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 1173000, "totalCashPerShare": 0.07, "ebitda": -11390000, "quickRatio": 0.998, "currentRatio": 1.248, "returnOnAssets": -1.6315401, "returnOnEquity": -6.46981, "freeCashflow": -5439500, "operatingCashflow": -10258000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]